Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — Q4 2023 Earnings Presentation
26 slides from Inovio Pharmaceuticals's earnings presentation, Mar 6, 2024
Slide 1: Fourth Quarter & Full Year 2023 Financial Results
Fourth Quarter & Full Year 2023 Financial Results March 6, 2024 :INO 1
Slide 2: Fourth Quarter & Full Year 2023 Financial Results Agenda
Fourth Quarter & Full Year 2023 Financial Results Welcome, Fourth Quarter Highlights & Pipeline Review • Jacqueline Shea, PhD, President and CEO Regulatory & Medical Affairs Update • Michael Sumner, MBBS, MBA, Chief Medical Officer Commercial Update • Mark Twyman, MBA, Chief Commercial Officer Finan
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,”” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding
Slide 4: Welcome: Review of 2023 & Recent Progress
Welcome: Review of 2023 & Recent Progress 4
Slide 5: Progress Over Last Twelve Months
Progress Over Last Twelve Months • Prioritized pipeline, reshaped organization to focus on candidates with greatest clinical promise, achievable pathways to market and strong commercial potential • Reduced operating expenses nearly in half over the past year • Substantial progress with lead candidat
Slide 6: 2024 Key Catalysts
2024 Key Catalysts • Finalize trial design for INO-3112 in throat • INO-3107: Submit BLA, initiate cancer confirmatory trial • Determine next steps for INO-5401 in GBM • First clinical data from Phase 1 dMAb trial • Finalize plans for INO-4201 Ebola booster (anti-SARS-CoV-2) based on FDA feedback, d
Slide 7: Regulatory & Medical Affairs Update
Regulatory & Medical Affairs Update 7
Slide 8: Recurrent Respiratory Papillomatosis (RRP)
Recurrent Respiratory Papillomatosis (RRP) • Rare disease characterized by small, wart-like growths (papillomas) in the respiratory tract • Can form anywhere but primarily affect larynx & vocal cords • Can cause difficulty speaking or complete voice loss, difficulty swallowing, shortness of breath a
Slide 9: RRP Foundation President quote
“ RRP patients will tell you that even one reduction in the number of disruptive, invasive surgeries they face would be life-changing. The potential impact of this treatment gives me great hope for the future and I'm happy to see that RRP is finally getting the attention it deserves.” – Kim McClella
Slide 10: INO-3107: In Phase 1/2 trial 81.3% of participants had a decrease in surgeries
INO-3107: In Phase 1/2 trial 81.3% of participants had a decrease in surgeries 10 Includes surgeries performed during the dosing window.
Slide 11: INO-3107: Accelerated Progress
INO-3107: Accelerated Progress • Positive Ph 1/2 trial results – both cohorts • Results published in Laryngoscope • Orphan Drug designation – U.S. • Orphan Drug designation – EU • First patient dosed in Ph 1/2 trial • Breakthrough Therapy designation 2020 2021 2022 2023 2024 • Positive Ph 1/2 trial
Slide 12: Key Catalysts for INO-3107 in 2024
Key Catalysts for INO-3107 in 2024 • Completing submission of BLA under accelerated approval program 2H24 • Initiating confirmatory trial prior to BLA submission • Requesting rolling submission and Priority Review – possible action on application within ~6 months (compared to usual ~10 month review)
Slide 13: INO-3112: Clinical Collaboration and Supply Agreement with Coherus BioSciences
INO-3112: Clinical Collaboration and Supply Agreement with Coherus BioSciences INO-3112: DNA medicine candidate LOQTORZI: Proven anti-PD-1 monoclonal targeting HPV-16/18, combined with antibody interleukin-12 (immune activator) Will evaluate combination therapy as treatment for locoregionally advanc
Slide 14: What is Oropharyngeal Squamous Cell Carcinoma?
What is Oropharyngeal Squamous Cell Carcinoma? • Type of head and neck cancer commonly known as throat cancer • Occurs in the base of the tongue, tonsils and/or soft palate • Typically causally related to high-risk subtypes of HPV, some cases are carcinogen-driven • HPV+ throat cancer rapidly increa
Slide 15: HPV-Related Locoregionally Advanced Throat Cancer
HPV-Related Locoregionally Advanced Throat Cancer Unmet need exists in preventing relapse in high-risk patients • Most throat cancer patients diagnosed with locoregionally advanced (LA) disease • Current treatment: ◦ Curative intent through use of multi-modal therapy, including surgery & CRT • Outco
Slide 16: INO-3112: Previously Completed Trials
INO-3112: Previously Completed Trials Monotherapy: Phase 1/2a in pre-surgery or Combination Therapy: Phase 1b/2a in post CRT patient recurrent/metastatic patients • Combined with AstraZeneca’s PD-L1 checkpoint Published in Clinical Cancer Research, 2019 inhibitor, durvalumab • ORR: 27.6% (4 CR, 4 PR
Slide 17: Commercial Update
Commercial Update 17
Slide 18: INO-3107: On Track to Launch in 2025
INO-3107: On Track to Launch in 2025 • Dedicated to understanding patients and their experiences ◦ Continuing to build insights into patient journey ◦ Advisory board panels held in Q4 • Mapping the HCP landscape ◦ Initiated comprehensive market analysis of RRP HCPs ◦ Will allow us to focus field dep
Slide 19: Key Characteristics for INO-3107
Key Characteristics for INO-3107 Clinical Advantages Commercial Advantages • Completed Phase 1/2 trial • Targets/similar efficacy against both HPV-6 - Can be used to file BLA under and HPV-11 (strains that cause RRP) accelerated approval program • Potential for redosing • Significant efficacy data &
Slide 20: Pipeline Update
Pipeline Update 20
Slide 21: INOVIO Pipeline
INOVIO Pipeline PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATION dMAb INO-5401 VGX-3100 INO-3107* Influenza BRCA1/2 Mutation Anal Dysplasia RRP dLNPs INO-4201 INO-3112 Various targets Ebola Booster Head & Neck Cancer INO-6172 INO-5401 HIV Glioblastoma INO-6160 HIV dMAbs COVID-19 OUT-LICENSED** PRECL
Slide 22: Financial Update
Financial Update 22
Slide 23: Commitment to Financial Discipline Key to Strategy
Commitment to Financial Discipline Key to Strategy Total Operating Expense Financial Strengths 4th Quarter Year End 2022 vs. 2023 2022 vs. 2023 • $145.3M in cash, $56.1M $277.8M cash equivalents, short-term investments as of 12/31/23 -51% -48% • Cash runway into 2Q 2025 • Operational cash burn of $2
Slide 24: Q&A
Q&A 24
Slide 25: 2024 Key Catalysts
2024 Key Catalysts • Finalize trial design for INO-3112 in throat • INO-3107: Submit BLA, initiate cancer confirmatory trial • Determine next steps for INO-5401 in GBM • First clinical data from Phase 1 dMAb trial • Finalize plans for INO-4201 Ebola booster (anti-SARS-CoV-2) based on FDA feedback, d
Slide 26: Thank you.
Thank you. 26
Inovio Pharmaceuticals — Q4 2023 Earnings Presentation on 6ix